We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

70 hedge funds and large institutions have $127M invested in Concert Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 6

274% more call options, than puts

Call options by funds: $747K | Put options by funds: $200K

189% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 9

119% more capital invested

Capital invested by funds: $58M → $127M (+$69.2M)

32% more funds holding

Funds holding: 53 → 70 (+17)

Holders
70
Holders Change
+17
Holders Change %
+32.08%
% of All Funds
1.18%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
26
Reduced
9
Closed
6
Calls
$747K
Puts
$200K
Net Calls
+$547K
Net Calls Change
+$549K

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$6.57M
2
BI
BVF Inc
California
+$5.44M
3
KCM
Kynam Capital Management
New Jersey
+$3.96M
4
EI
EAM Investors
California
+$3.37M
5
PHP
Parkman Healthcare Partners
Connecticut
+$2.95M

Top Sellers

Rank Fund Capital Flow
1
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$132K
2
Charles Schwab
Charles Schwab
California
-$80K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$61.2K
4
Jane Street
Jane Street
New York
-$56K
5
BlackRock
BlackRock
New York
-$49.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.03M -$34.9K -8,811 -3%
Two Sigma Investments
27
Two Sigma Investments
New York
$1M +$896K +226,476 +1,887%
Walleye Capital
28
Walleye Capital
New York
$840K +$789K +199,500 New
Goldman Sachs
29
Goldman Sachs
New York
$789K +$742K +187,488 New
BCM
30
Bridgeway Capital Management
Texas
$624K +$218K +55,000 +59%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$621K +$324K +82,000 +125%
IBT
32
International Biotechnology Trust
United Kingdom
$620K +$10.3K +2,610 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$598K +$491K +124,206 +694%
SEI Investments
34
SEI Investments
Pennsylvania
$461K +$434K +109,596 New
CAM
35
ClariVest Asset Management
California
$441K +$415K +104,800 New
State Street
36
State Street
Massachusetts
$429K +$103K +26,100 +34%
Northern Trust
37
Northern Trust
Illinois
$410K -$7.9K -1,997 -2%
CSS
38
Cubist Systematic Strategies
Connecticut
$379K +$357K +90,123 New
Marshall Wace
39
Marshall Wace
United Kingdom
$374K +$353K +89,146 New
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$372K +$350K +88,341 New
KIC
41
Kensington Investment Counsel
California
$321K -$1.56K -395 -0.5%
Franklin Resources
42
Franklin Resources
California
$295K +$277K +70,000 New
RC
43
RBF Capital
California
$294K – – –
BDF
44
Black Diamond Financial
Maryland
$290K +$91K +23,000 +50%
VF
45
Virtu Financial
New York
$275K +$204K +51,489 +370%
SSA
46
Schonfeld Strategic Advisors
New York
$251K +$236K +59,600 New
JP Morgan Chase
47
JP Morgan Chase
New York
$195K +$183K +46,307 +110,255%
Tudor Investment Corp
48
Tudor Investment Corp
Connecticut
$192K – – –
PVI
49
Pura Vida Investments
New York
$187K +$176K +44,357 New
LSAG
50
Lake Street Advisors Group
New Hampshire
$149K – – –
1
2
3

CNCE Hedge Fund Activity: Q2 2022 in Review

70 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2022, worth a combined $127M — up 119% from $58M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CNCE positions and 6 closed out — a net gain of 17 holders — while 26 added to existing stakes and 9 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $6.57M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $132K.

  • 70 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2022, up from 53 in Q1 2022.
  • Funds reported $127M of Concert Pharmaceuticals, Inc. stock for Q2 2022, up 119% quarter-over-quarter.
  • 23 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2022 and 6 closed out, a net change of +17 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q2 2022 was Nantahala Capital Management, an estimated $6.57M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q2 2022 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $132K sold.

Based on aggregated 13F filings for Q2 2022.